REFERENCES
- Moellering RCJr. Linezolid: the first oxazolidinone an-timicrobial. Ann Intern Med 2003; 138 (2): 135–142.
- French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 (90002): 45ii-53.
- Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B et al. Hematologic effects of linezolid: summary of clin-ical experience. Antimicrob Agents Chemother 2002; 46 (8): 2723–2726.
- Lee E, Burger S, Shah J, Melton C, Mullen M, Warren F et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37 (10): 1389-1391.
- Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364 (9431): 369–379.
- Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-Joint infections. N Engl J Med 2004; 351 (16): 1645–1654.
- Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin N Amer 2005; 19 (4): 765–786.
- Velasco D, del Mar TM, Cartelle M, Beceiro A, Perez A, Molina F et al. Evaluation of different methods for detecting me-thicillin (oxacillin) resistance in Staphylococcus aureus. J An-timicrob Chemother 2005; 55 (3): 379-382.
- Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38 (1): 17–24.
- Senneville E, Legout L, Valette M, Yazdanpanah Y, Bel-trand E, Caillaux M et al. Effectiveness and Tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28 (8): 1155–1163.
- Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004; 79 (9): 1137–1144.
- Lovering AM, Zhang J, Bannister GC, Lankester BJA, Brown JHM, Narendra G et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50 (1): 73–77.
- Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17 (6): 643–650.
- Bassetti M, Righi E, Di BA, Rosso R, Beltrame A, Bassetti D. Role of linezolid in the treatment of orthopedic infections. Ex-pert Rev Anti Infect Ther 2005; 3 (3): 343–352.
- Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of os-teomyelitis: results of compassionate use experience. Infection 2004; 32 (1): 8–14.
- Bassetti M, Di Biagio A, Cenderello G, Del Bono V, Palermo A, Cruciani M et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect 2001; 43 (2): 148-149.
- Rao N, Ziran BH, Hall RA, Santa ER. Successful treat-ment of chronic bone and joint infections with oral linezolid. Clin Orthop Relat Res 2004; (427): 67-71.
- Senneville E, Legout L, Valette M, Yazdanpanah Y, Gi-raud F, Beltrand E et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-con-trol study. J Antimicrob Chemother 2004; 54 (4): 798–802.
- Vercillo M, Patzakis MJ, Holtom P, Zalavras CG. Linezolid in the treatment of implant-related chronic osteomyelitis. Clin Orthop Relat Res 2007; 461: 40–43.
- Wu VC, Wang YT, Wang CY, Tsai U, Wu KD, Hwang JJ et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42 (1): 66–72.
- Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombo-cytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34 (5): 695–698.
- Bassetti M, Vitale F, Melica G, Righi E, Di Biagio A, Molfetta L et al. Linezolid in the treatment of gram-positive pros-thetic joint infections. J Antimicrob Chemother 2005; 55 (3): 387–390.